Welcome to our dedicated page for Merck & Co news (Ticker: MRK), a resource for investors and traders seeking the latest updates and insights on Merck & Co stock.
Merck & Co. (NYSE: MRK) is a global pharmaceutical leader with a 350-year legacy of medical innovation. This news hub provides investors and healthcare professionals with direct access to official announcements, financial disclosures, and research developments shaping the company's trajectory.
Track MRK's latest regulatory milestones, clinical trial results, and strategic partnerships through verified press releases and curated analysis. Our repository includes earnings call transcripts, FDA approval updates, and global health initiatives—all organized for efficient research and due diligence.
Key updates on therapeutic advancements in oncology, vaccines, and infectious diseases are maintained alongside financial performance data. Bookmark this page for real-time access to Merck's corporate communications and market-moving developments in the pharmaceutical sector.
Merck (NYSE: MRK) announced that the CDC's Advisory Committee on Immunization Practices (ACIP) has unanimously recommended updates to pneumococcal vaccination for adults 65 and older, and adults 19 to 64 with specific health conditions. The committee suggested a sequential regimen of VAXNEUVANCE followed by PNEUMOVAX 23, or a single dose of the 20-valent vaccine. These recommendations aim to address the significant unmet need for preventing invasive pneumococcal disease (IPD) among at-risk populations. The final guidelines will be published in the CDC’s MMWR.
Darwin Global Management has issued a letter urging shareholders of Acceleron Pharma Inc. (XLRN) to reject Merck's (MRK) proposed acquisition offer of
Merck (NYSE: MRK) is voluntarily recalling one lot of CUBICIN® (daptomycin for injection) due to a customer complaint reporting glass contamination in the vials. Approximately 22,000 vials from Lot 934778, expiring in June 2022, are affected. The recall is initiated to the user level and aims to prevent serious health risks associated with glass infusion. To date, there have been no reported adverse events linked to this issue. Customers with affected vials are instructed to contact Sedgwick for return instructions and prepaid shipping labels.
Merck (NYSE: MRK) and Eisai announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has issued positive opinions for the combination of KEYTRUDA and LENVIMA. This therapy targets advanced renal cell carcinoma (RCC) and advanced endometrial carcinoma (EC), showing significant improvements in overall survival (OS) and progression-free survival (PFS) in clinical trials. In the CLEAR/KEYNOTE-581 trial, KEYTRUDA plus LENVIMA reduced the risk of death by 34% and disease progression by 61% compared to sunitinib. The decision from the European Commission is expected by Q4 2021.
Merck (NYSE: MRK) announced that the European Medicines Agency’s CHMP has recommended the approval of VAXNEUVANCE, a 15-valent pneumococcal conjugate vaccine, for immunization against invasive disease and pneumonia caused by Streptococcus pneumoniae in adults 18 years and older. This recommendation is pending review by the European Commission, with a decision expected by year-end. VAXNEUVANCE is already FDA-approved in the U.S. for similar indications. The vaccine addresses the growing global prevalence of pneumococcal disease, particularly among vulnerable populations.
Holocene Advisors, a significant shareholder of Acceleron Pharma (XLRN), announced it will not tender its shares into Merck's (MRK) $180 per share offer. Holocene stated that the offer undervalues Acceleron, based on analysis and its strong pipeline, particularly the drug sotatercept, which shows promise for treating pulmonary arterial hypertension and could generate substantial sales. Holocene expressed concerns that proceeding with the current offer would deprive XLRN shareholders of significant value and highlighted the potential for increased value as more clinical data becomes available.
Merck (NYSE: MRK) has received FDA approval for KEYTRUDA in combination with chemotherapy, with or without bevacizumab, as a first-line treatment for patients with persistent, recurrent, or metastatic cervical cancer whose tumors express PD-L1 (CPS ≥1). The approval is based on Phase 3 KEYNOTE-826 trial results, demonstrating improved overall survival (OS) and progression-free survival (PFS) with KEYTRUDA compared to chemotherapy alone. This marks an important advancement in treatment options for women with cervical cancer, particularly given the low survival rates in this population.
Merck (NYSE: MRK) has launched a cash tender offer for all outstanding shares of Acceleron Pharma Inc. (NASDAQ: XLRN), following their definitive acquisition agreement announced on Sept. 30, 2021.
Stockholders of Acceleron will receive $180 per share upon successful closing. The tender offer expires at 5:00 p.m. ET on Nov. 10, 2021. The deal is contingent upon receiving regulatory approvals and the majority of Acceleron shares being tendered.
Organon (NYSE: OGN) announced FDA clearance for its updated Jada® System, designed to treat abnormal postpartum uterine bleeding effectively. Postpartum hemorrhage cases have risen significantly in the U.S. The updated system features a new kit configuration and improved ease of use, enhancing treatment options in maternal health. The reconfigured Jada system is set to be available in January 2022. This strategic move follows Organon's acquisition of Alydia Health, reinforcing its commitment to women's health.
Merck has submitted an Emergency Use Authorization (EUA) application to the U.S. FDA for molnupiravir, a new oral antiviral treatment for mild-to-moderate COVID-19 in high-risk adults. The decision follows positive results from the Phase 3 MOVe-OUT trial, showing a 50% reduction in hospitalization or death among treated patients compared to placebo. Merck aims to produce 10 million treatment courses by the end of 2021 and has secured supply agreements with the U.S. government and other nations, ensuring global access if authorized.
